vs
Side-by-side financial comparison of SOLESENCE, INC. (SLSN) and TriSalus Life Sciences, Inc. (TLSI). Click either name above to swap in a different company.
TriSalus Life Sciences, Inc. is the larger business by last-quarter revenue ($13.2M vs $12.5M, roughly 1.1× SOLESENCE, INC.). SOLESENCE, INC. runs the higher net margin — 1.3% vs -73.9%, a 75.2% gap on every dollar of revenue. On growth, TriSalus Life Sciences, Inc. posted the faster year-over-year revenue change (59.8% vs -0.7%). Over the past eight quarters, TriSalus Life Sciences, Inc.'s revenue compounded faster (43.0% CAGR vs 12.5%).
TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on advancing immuno-oncology and interventional oncology solutions. It develops proprietary targeted drug delivery technologies designed to improve treatment efficacy for patients with liver, pancreatic and other hard-to-treat solid tumors, primarily operating in North American markets via partnerships with clinical care and research institutions.
SLSN vs TLSI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.5M | $13.2M |
| Net Profit | $163.0K | $-9.8M |
| Gross Margin | 27.5% | 86.7% |
| Operating Margin | 1.5% | -24.8% |
| Net Margin | 1.3% | -73.9% |
| Revenue YoY | -0.7% | 59.8% |
| Net Profit YoY | 129.2% | 3.5% |
| EPS (diluted) | $0.00 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.5M | $13.2M | ||
| Q3 25 | $14.6M | $11.6M | ||
| Q2 25 | $20.4M | $11.2M | ||
| Q1 25 | $14.6M | $9.2M | ||
| Q4 24 | $12.6M | $8.3M | ||
| Q3 24 | $16.9M | $7.3M | ||
| Q2 24 | $13.0M | $7.4M | ||
| Q1 24 | $9.9M | $6.5M |
| Q4 25 | $163.0K | $-9.8M | ||
| Q3 25 | $-1.1M | $-10.8M | ||
| Q2 25 | $2.7M | $-8.3M | ||
| Q1 25 | $80.0K | $-10.4M | ||
| Q4 24 | $-559.0K | $-10.1M | ||
| Q3 24 | $3.0M | $-2.4M | ||
| Q2 24 | $856.0K | $-4.3M | ||
| Q1 24 | $893.0K | $-13.2M |
| Q4 25 | 27.5% | 86.7% | ||
| Q3 25 | 23.1% | 83.5% | ||
| Q2 25 | 28.9% | 83.9% | ||
| Q1 25 | 23.1% | 83.7% | ||
| Q4 24 | 22.0% | 85.3% | ||
| Q3 24 | 36.2% | 86.3% | ||
| Q2 24 | 28.7% | 87.6% | ||
| Q1 24 | 36.3% | 85.0% |
| Q4 25 | 1.5% | -24.8% | ||
| Q3 25 | -5.4% | -77.9% | ||
| Q2 25 | 9.4% | -65.4% | ||
| Q1 25 | 1.8% | -79.9% | ||
| Q4 24 | -1.8% | -91.8% | ||
| Q3 24 | 19.0% | -118.9% | ||
| Q2 24 | 8.0% | -111.0% | ||
| Q1 24 | 11.3% | -180.8% |
| Q4 25 | 1.3% | -73.9% | ||
| Q3 25 | -7.7% | -93.5% | ||
| Q2 25 | 13.1% | -73.9% | ||
| Q1 25 | 0.5% | -113.2% | ||
| Q4 24 | -4.4% | -122.4% | ||
| Q3 24 | 18.1% | -32.6% | ||
| Q2 24 | 6.6% | -58.8% | ||
| Q1 24 | 9.0% | -204.5% |
| Q4 25 | $0.00 | $-0.22 | ||
| Q3 25 | $-0.02 | $-0.96 | ||
| Q2 25 | $0.04 | $-0.27 | ||
| Q1 25 | $0.00 | $-0.39 | ||
| Q4 24 | $0.00 | $-0.38 | ||
| Q3 24 | $0.04 | $-0.12 | ||
| Q2 24 | $0.01 | $-0.21 | ||
| Q1 24 | $0.02 | $-0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $17.6M | $-33.9M |
| Total Assets | $50.1M | $35.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3M | $20.4M | ||
| Q3 25 | $429.0K | $22.7M | ||
| Q2 25 | $4.1M | $26.5M | ||
| Q1 25 | $1.8M | $13.0M | ||
| Q4 24 | $1.4M | $8.5M | ||
| Q3 24 | $2.9M | $11.3M | ||
| Q2 24 | $2.4M | $16.5M | ||
| Q1 24 | $2.0M | $4.0M |
| Q4 25 | $17.6M | $-33.9M | ||
| Q3 25 | $17.2M | $-26.7M | ||
| Q2 25 | $18.2M | $-19.4M | ||
| Q1 25 | $15.2M | $-34.4M | ||
| Q4 24 | $14.9M | $-25.9M | ||
| Q3 24 | $15.2M | $-20.4M | ||
| Q2 24 | $11.9M | $-25.3M | ||
| Q1 24 | $5.0M | $-36.0M |
| Q4 25 | $50.1M | $35.3M | ||
| Q3 25 | $54.0M | $36.5M | ||
| Q2 25 | $60.0M | $41.3M | ||
| Q1 25 | $57.0M | $28.6M | ||
| Q4 24 | $50.0M | $24.0M | ||
| Q3 24 | $48.0M | $27.5M | ||
| Q2 24 | $40.8M | $32.4M | ||
| Q1 24 | $38.5M | $17.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $-2.5M |
| Free Cash FlowOCF − Capex | — | $-2.5M |
| FCF MarginFCF / Revenue | — | -19.1% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | 11.16× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-19.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | $-2.5M | ||
| Q3 25 | $-2.5M | $-3.7M | ||
| Q2 25 | $-654.0K | $-7.3M | ||
| Q1 25 | $-7.2M | $-4.5M | ||
| Q4 24 | $2.2M | $-5.7M | ||
| Q3 24 | $4.2M | $-10.8M | ||
| Q2 24 | $-565.0K | $-13.4M | ||
| Q1 24 | $-3.9M | $-10.9M |
| Q4 25 | — | $-2.5M | ||
| Q3 25 | — | $-3.9M | ||
| Q2 25 | — | $-7.4M | ||
| Q1 25 | — | $-5.3M | ||
| Q4 24 | $-404.0K | $-5.8M | ||
| Q3 24 | $2.8M | $-11.0M | ||
| Q2 24 | $-1.0M | $-13.5M | ||
| Q1 24 | $-3.9M | $-10.9M |
| Q4 25 | — | -19.1% | ||
| Q3 25 | — | -33.9% | ||
| Q2 25 | — | -66.1% | ||
| Q1 25 | — | -57.3% | ||
| Q4 24 | -3.2% | -69.7% | ||
| Q3 24 | 16.6% | -149.9% | ||
| Q2 24 | -8.0% | -183.1% | ||
| Q1 24 | -39.9% | -169.3% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 8.2% | ||
| Q4 24 | 20.6% | 0.6% | ||
| Q3 24 | 8.3% | 2.3% | ||
| Q2 24 | 3.7% | 0.8% | ||
| Q1 24 | 0.9% | 1.0% |
| Q4 25 | 11.16× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.25× | — | ||
| Q1 25 | -90.26× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | -0.66× | — | ||
| Q1 24 | -4.32× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
